VIENNA, Va., June 18, 2024--CEL-SCI Corporation (NYSE American: CVM) today announced the Company’s Chief Scientific Officer, Dr. Eyal Talor, delivered a presentation titled "Neoadjuvant Immunotherapy for Head and Neck Cancer: Low Tumor PD-L1 Expression - IT-MATTERS – RCT" at the International Drug Discovery Science & Technology (IDDST) 20th Annual Congress in Budapest, Hungary on Tuesday, June 18, 2024. Dr. Talor presented during the Cancers/Tumors session which he Chaired along with Dr. Elizabe
VIENNA, Va., June 06, 2024--Dr. Giovanni Selvaggi, who has brought several oncology drugs to market, joins CEL-SCI as Clinical Advisor.
VIENNA, Va., May 16, 2024--CEL-SCI Corporation reports second quarter fiscal 2024 financial results.